Cencora, Inc. (NYSE:COR) Given Average Rating of “Moderate Buy” by Analysts

Shares of Cencora, Inc. (NYSE:COR) have earned an average rating of “Moderate Buy” from the thirteen analysts that are covering the company, MarketBeat.com reports. Two analysts have rated the stock with a hold recommendation and eleven have issued a buy recommendation on the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $399.00.

A number of research analysts have weighed in on COR shares. Jefferies Financial Group upgraded Cencora from an “underperform” rating to a “buy” rating in a report on Thursday, January 22nd. Bank of America reduced their price target on Cencora from $380.00 to $360.00 and set a “neutral” rating on the stock in a research note on Monday, January 5th. TD Cowen increased their price objective on Cencora from $350.00 to $400.00 and gave the stock a “buy” rating in a report on Monday, November 10th. JPMorgan Chase & Co. boosted their target price on shares of Cencora from $417.00 to $419.00 and gave the company an “overweight” rating in a report on Tuesday, February 10th. Finally, Wells Fargo & Company upped their target price on shares of Cencora from $405.00 to $429.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 10th.

Insider Activity

In other Cencora news, CEO Robert P. Mauch sold 5,096 shares of Cencora stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $354.73, for a total transaction of $1,807,704.08. Following the completion of the transaction, the chief executive officer owned 66,726 shares in the company, valued at approximately $23,669,713.98. The trade was a 7.10% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Silvana Battaglia sold 1,677 shares of the business’s stock in a transaction on Friday, December 19th. The stock was sold at an average price of $345.00, for a total value of $578,565.00. Following the completion of the sale, the executive vice president directly owned 18,796 shares in the company, valued at $6,484,620. This trade represents a 8.19% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 15,220 shares of company stock worth $5,282,867. Insiders own 0.38% of the company’s stock.

Hedge Funds Weigh In On Cencora

Several large investors have recently modified their holdings of COR. Vanguard Group Inc. raised its holdings in Cencora by 0.9% in the fourth quarter. Vanguard Group Inc. now owns 23,617,117 shares of the company’s stock worth $7,976,681,000 after buying an additional 221,570 shares during the last quarter. State Street Corp increased its position in shares of Cencora by 1.3% during the fourth quarter. State Street Corp now owns 9,305,507 shares of the company’s stock valued at $3,142,935,000 after acquiring an additional 115,191 shares in the last quarter. Geode Capital Management LLC raised its holdings in Cencora by 3.2% in the 4th quarter. Geode Capital Management LLC now owns 5,459,476 shares of the company’s stock worth $1,843,268,000 after acquiring an additional 169,055 shares during the last quarter. JPMorgan Chase & Co. lifted its position in Cencora by 6.5% in the 4th quarter. JPMorgan Chase & Co. now owns 4,982,557 shares of the company’s stock valued at $1,682,859,000 after acquiring an additional 304,760 shares in the last quarter. Finally, T. Rowe Price Investment Management Inc. lifted its position in Cencora by 80.9% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 4,661,769 shares of the company’s stock valued at $1,574,513,000 after acquiring an additional 2,085,473 shares in the last quarter. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Cencora Trading Down 0.2%

NYSE:COR opened at $359.98 on Wednesday. The company has a 50-day moving average price of $348.42 and a 200-day moving average price of $329.91. Cencora has a 12 month low of $237.71 and a 12 month high of $377.54. The company has a current ratio of 0.92, a quick ratio of 0.51 and a debt-to-equity ratio of 3.62. The stock has a market cap of $70.03 billion, a price-to-earnings ratio of 43.27, a P/E/G ratio of 1.66 and a beta of 0.68.

Cencora (NYSE:COR) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $4.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.04 by $0.04. Cencora had a net margin of 0.50% and a return on equity of 176.54%. The company had revenue of $85.93 billion for the quarter, compared to analysts’ expectations of $86.12 billion. During the same quarter in the previous year, the company earned $3.73 earnings per share. Cencora’s quarterly revenue was up 5.5% on a year-over-year basis. Equities analysts predict that Cencora will post 15.37 EPS for the current year.

Cencora Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 2nd. Shareholders of record on Friday, February 13th will be paid a dividend of $0.60 per share. The ex-dividend date of this dividend is Friday, February 13th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.7%. Cencora’s dividend payout ratio (DPR) is currently 28.85%.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.